Publication

Article

Oncology Live®
May 2011
Volume 12
Issue 5

Canine DNA Yields Clues to Human Lymphomas

Researchers at North Carolina State University used canines as genetic models for studying lymphomas

Canine DNA used in Lymphoma research

In order to learn more about the genetic causes of non-Hodgkin lymphoma (NHL), scientists are going to the dogs—literally.

Researchers at North Carolina State University used canines as genetic models for studying lymphomas based on the theory that analyzing the restricted genetic variation of purebred dogs would enable them to pinpoint NHL-associated aberrations in chromosomes that are difficult to distinguish in humans.

To conduct their study, investigators surveyed 150 non-random canine NHL cases. Thomas et al reported in Leukemia & Lymphoma that they found limited genomic instability when compared with data from humans, and no evidence for CDKN2A/B deletion in canine B-cell NHL. (Published online ahead of print March 7, 2011. doi:10.3109/1042819 4.2011.559802.)

“‘Genomic recoding’ of canine NHL data into a ‘virtual human’ chromosome format showed remarkably few regions of copy number aberration (CNA) shared between both species, restricted regions of dog chromosomes 13 and 31, and human chromosomes 8 and 21,” researchers said in their abstract.

They said more clues about NHL genes in humans might be gleaned by further study of the “less complex association between CNAs and tumor pathogenesis in canine patients.”

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study